BioSpace News Archive

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted five employees nonqualified stock options to purchase 131,000 shares of its common stock with an exercise price of $7.10 per share, which is equal to the closing price of Kezar’s common stock on February 3, 2023, the grant date of the awards.

Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 7 new employees inducement stock options to purchase an aggregate of 70,070 common shares, at a per share exercise price of $9.05, the closing price of Aurinia’s common stock on February 3, 2023, and an aggregate of 43,160 inducement restricted stock units.

Collegium Pharmaceutical, Inc. announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2022.

MacroGenics, Inc. announced that the Company’s management will participate in the following investor conferences in February 2023:

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that management will participate in three upcoming investor conferences.

Azenta, Inc. will announce fiscal first quarter 2023 earnings which ended on December 31, 2022 on Wednesday, February 8, 2023 after the market closes.

Aracari Biosciences expands to new headquarters in Irvine, California after incubating for 3 years at University Lab Partners, the premier life science incubator in Irvine.

Medexus Pharmaceuticals is pleased to welcome Harmony P. Garges MD MPH, Chief Medical Officer of ViiV Healthcare, and Menassie Taddese MBA, former executive at Pfizer and Viatris, to the Medexus board of directors.

Atreca, Inc. (Atreca) (NASDAQ: BCEL) and Xencor, Inc. (NASDAQ: XNCR) today announced, as part of their existing strategic collaboration, they have mutually selected the first program combining an Atreca-discovered antibody with Xencor’s XmAb® bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).